Obstetric and Gynecologic Imaging

What Is the Right Imaging for Surveillance of Gestational Trophoblastic Neoplasia?

·
What Is the Right Imaging for Surveillance of Gestational Trophoblastic Neoplasia?

A 32-year-old patient with a history of a complete hydatidiform mole, treated with single-agent chemotherapy, returns for her follow-up appointment. Her serial beta-human chorionic gonadotropin (β-hCG) levels, which had been steadily declining, have now plateaued for three consecutive weeks. The gynecologic oncologist is concerned about refractory Gestational Trophoblastic Neoplasia (GTN) and needs to determine if there is persistent, chemotherapy-resistant disease within the uterus or evidence of distant metastases. The immediate clinical question is which imaging study to order first to evaluate the pelvis. According to the American College of Radiology (ACR) Appropriateness Criteria, for surveillance of GTN, including refractory or relapsed disease, a US duplex Doppler pelvis is Usually appropriate.

Who Fits This Clinical Scenario for Gestational Trophoblastic Neoplasia Surveillance?

This guidance is specifically for patients with an established diagnosis of Gestational Trophoblastic Neoplasia (GTN) who are undergoing surveillance. This includes several distinct clinical situations:

  • Refractory GTN: Patients currently undergoing chemotherapy whose β-hCG levels plateau or begin to rise, suggesting the tumor is resistant to the current treatment regimen.
  • Relapsed GTN: Patients who achieved remission (normal β-hCG levels) after treatment but now present with a subsequent rise in β-hCG, indicating disease recurrence.
  • Quiescent GTN: A rare situation where patients have persistently low levels of β-hCG (typically <200 mIU/mL) for months or years after initial treatment, without evidence of active tumor on imaging. Surveillance helps monitor for any change.

This workflow is distinct from other clinical presentations. It does not apply to the initial workup of a suspected molar pregnancy, which falls under the Suspected or initial diagnosis of gestational trophoblastic disease scenario. It is also separate from the comprehensive imaging required for the initial staging of a newly diagnosed GTN, which is covered in the Staging and risk assessment scenario. Finally, it is not intended for patients presenting with acute complications like uterine hemorrhage.

What Diagnoses Are You Working Up in This Surveillance Scenario?

When β-hCG levels fail to normalize or rise after treatment, imaging is directed at identifying the source. The differential diagnosis in this surveillance context is focused and consequential.

Persistent or Recurrent Uterine GTN
This is the primary concern and the most common reason for abnormal β-hCG levels in this setting. Chemotherapy-resistant trophoblastic tissue may persist as a discrete, vascular mass within the myometrium. Identifying the location, size, and vascularity of this persistent tumor is critical for guiding the next line of therapy, which may involve multi-agent chemotherapy or surgical intervention like hysterectomy.

Uterine Arteriovenous Malformation (AVM)
An acquired uterine AVM is a less common but critical differential. It can develop after uterine instrumentation, such as a dilation and curettage (D&C) procedure, and presents as a tangle of vessels within the myometrium. While it does not produce β-hCG, it can be a source of significant bleeding and can be mistaken for a vascular tumor. Duplex Doppler is essential for characterizing the high-flow, low-resistance waveform of an AVM, distinguishing it from the neovascularity of a tumor.

Metastatic Disease
If the pelvis is clear, the source of the elevated β-hCG must be an occult metastasis. GTN most commonly metastasizes to the lungs, followed by the vagina, liver, and brain. While pelvic ultrasound is the first step to evaluate the primary site, a negative pelvic study in the face of rising β-hCG immediately shifts the focus to a systemic search for distant disease.

Why Is US duplex Doppler pelvis the Recommended Initial Study for GTN Surveillance?

The ACR panel rates US duplex Doppler pelvis as Usually appropriate because it directly, safely, and effectively addresses the primary clinical question: is there persistent, vascular disease in the uterus?

The strength of ultrasound lies in its ability to visualize the myometrium with high resolution without using ionizing radiation (adult RRL=O 0 mSv). This is particularly important in patients of reproductive age who may undergo multiple surveillance scans. The transvaginal approach, also rated Usually appropriate, provides superior detail of the endometrium and myometrium. The addition of color and spectral Doppler is not just an add-on; it is fundamental to the workup. It allows for the characterization of blood flow within any identified lesion, helping to distinguish hypervascular recurrent GTN from a non-neoplastic process like an AVM or retained products of conception.

Other powerful imaging modalities are available but are reserved for specific indications in this scenario:

  • MRI pelvis without and with IV contrast is rated May be appropriate. It serves as an excellent problem-solving tool if ultrasound findings are equivocal. MRI provides superior soft-tissue contrast and can more precisely define the extent of myometrial invasion, which can be valuable for surgical planning. However, it is more costly and less accessible than ultrasound, making it a secondary choice for initial surveillance.
  • CT abdomen and pelvis with IV contrast is rated Usually appropriate, but its role is different. It is not the primary modality for evaluating the uterus itself but is the workhorse for detecting metastatic disease in the abdomen, pelvis, and lungs (via a concurrent CT chest). It is typically ordered after a negative pelvic US or as part of a broader restaging workup when β-hCG levels are significantly elevated, suggesting a high tumor burden. It involves a moderate radiation dose (adult RRL=☢☢☢ 1-10 mSv).

For these reasons, the workflow begins with the safest and most direct tool for assessing the uterus. If the pelvic ultrasound is negative, the investigation then logically proceeds to cross-sectional imaging to search for metastatic sites.

What’s Next After US duplex Doppler pelvis? Downstream Workflow

The results of the pelvic ultrasound will guide the subsequent management pathway. The goal is to correlate the imaging findings with the β-hCG trend to make a definitive plan.

If the study is positive for a vascular uterine mass:
A finding consistent with persistent or recurrent GTN confirms the need for a change in management. This typically involves escalating to a multi-agent chemotherapy regimen or, in select cases of chemo-resistant, localized disease, considering surgical options such as hysterectomy or local resection. The imaging helps confirm that the source of β-hCG is uterine and provides a baseline to monitor treatment response.

If the study is negative and the pelvis is clear:
With a negative pelvic ultrasound but persistently elevated or rising β-hCG, the search must expand to find an extrauterine source. This immediately triggers a full metastatic workup, as outlined in the ACR’s staging scenario. This workup is Usually appropriate and includes CT of the chest, abdomen, and pelvis with IV contrast, and an MRI of the head without and with IV contrast to evaluate for lung, liver, and brain metastases.

If the study is indeterminate:
In cases where ultrasound reveals an ambiguous finding, such as abnormal vascularity that is not clearly a tumor or AVM, an MRI of the pelvis without and with IV contrast (May be appropriate) is the logical next step. Its superior tissue characterization can often resolve the diagnostic uncertainty and prevent unnecessary procedures.

Pitfalls to Avoid (and When to Get Help)

In the surveillance of GTN, several common errors can delay diagnosis or lead to inappropriate management.

  • Omitting Doppler: Ordering a pelvic ultrasound without specifying Duplex Doppler analysis is a major pitfall. The vascular signature is key to the differential diagnosis.
  • Ignoring the β-hCG trend: Imaging findings must always be interpreted in the context of serial β-hCG levels. A “normal” ultrasound in a patient with a rapidly rising β-hCG is not reassuring; it is an urgent indication to search for metastases.
  • Delaying metastatic workup: If pelvic imaging is negative, do not delay ordering chest/abdomen/pelvis CT and brain MRI. Occult metastases, particularly in the brain or liver, can progress rapidly and worsen the patient’s prognosis.

If there is any discrepancy between the imaging findings and the clinical picture, or if findings suggest a complex AVM, consultation with a gynecologic oncologist at a center with expertise in GTD is essential.

Related ACR Topics and Tools

This article focuses on a single clinical scenario. For a comprehensive overview of all variants and to understand how this scenario fits into the broader clinical context, please refer to the parent topic article. The following resources can also help in applying these guidelines.

Frequently Asked Questions

Why is ultrasound preferred over MRI for initial GTN surveillance of the pelvis?

Ultrasound with Duplex Doppler is preferred for initial surveillance because it is highly effective at visualizing uterine pathology, non-invasive, uses no ionizing radiation, is widely available, and is less expensive. It directly assesses the vascularity crucial for differentiating recurrent GTN from other conditions like an AVM. MRI is reserved as a problem-solving tool for equivocal ultrasound findings or for pre-surgical planning due to its higher cost and lower accessibility.

If the pelvic ultrasound is negative but β-hCG is still elevated, what is the next imaging step?

A negative pelvic ultrasound in the setting of elevated β-hCG strongly suggests extrauterine, metastatic disease. The immediate next step is a full metastatic workup, which includes a CT scan of the chest, abdomen, and pelvis with IV contrast, and an MRI of the head without and with IV contrast to search for common sites of metastasis like the lungs, liver, and brain.

What is the role of FDG-PET/CT in GTN surveillance?

According to the ACR, FDG-PET/CT is rated ‘May be appropriate’. It is not a first-line surveillance tool. Its primary role is as a problem-solving modality in complex cases, such as when β-hCG levels remain elevated but all conventional imaging (CT, MRI, US) is negative. In these situations, FDG-PET/CT can sometimes identify small, metabolically active tumor deposits that were otherwise occult.

Does a patient with quiescent GTN and stable, low β-hCG levels need regular imaging?

Patients with quiescent GTN are monitored primarily with serial β-hCG levels. Imaging, typically with pelvic ultrasound, is used at the initial assessment to rule out a discrete tumor and may be repeated if there is a change in the β-hCG trend or if new clinical symptoms develop. Routine, scheduled imaging in the absence of any clinical change is generally not required.

Is a chest radiograph sufficient to screen for lung metastases in relapsed GTN?

No. A chest radiograph is rated ‘Usually not appropriate’ for this scenario. It has low sensitivity for detecting small pulmonary nodules, which are a common manifestation of metastatic GTN. CT of the chest with IV contrast is the standard of care for evaluating the lungs in this context, as it is significantly more sensitive for identifying small-volume metastatic disease.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026